Our Take
Eli Lilly is enforcing compliance conditions unilaterally; hospitals have no regulatory shield yet, and HRSA's authority to force reversal is untested.
Why it matters
The 340B program is a $40+ billion safety-net mechanism that allows hospitals to buy drugs at steep discounts and reinvest savings into patient care. When a major pharma player unilaterally changes eligibility terms, it signals that statutory protections may not hold against vendor enforcement.
Do this week
Hospital supply chain leaders: audit your current Eli Lilly 340B paperwork trail this week against the company's new requirements so you can submit remedial documentation before next month's verification deadline.
Eli Lilly enforces new 340B compliance terms
Eli Lilly halted 340B discount pricing for hospitals that failed to meet newly imposed paperwork and verification requirements, effective late last week (per Healthcare Dive). The move follows the drugmaker's earlier announcement that it would tighten eligibility conditions for 340B participation.
The 340B Drug Pricing Program allows covered entities, including safety-net hospitals, to purchase medications at significantly reduced prices. Participating hospitals reinvest the savings into uncompensated care, outpatient services, and patient programs. Eli Lilly's action suspends discounts until hospitals comply with the company's new documentation standards.
Hospital groups have begun urging the Health Resources and Services Administration (HRSA), the federal agency that oversees the 340B program, to intervene and force reinstatement of discounts. The hospitals argue that Eli Lilly's new requirements exceed statutory obligations and amount to unilateral program modification.
Regulatory authority over vendor enforcement remains unclear
The 340B program operates under federal statute, but enforcement of participation terms has traditionally rested on a shared understanding: vendors comply with statutory definitions of eligible entities, and hospitals comply with accurate reporting. Eli Lilly's decision to impose additional conditions tests whether vendors have unilateral authority to add gates beyond statute.
If HRSA cannot or will not force reversal, the precedent is significant. Other pharma manufacturers may adopt similar tactics, effectively rewriting 340B eligibility on the fly. If HRSA does intervene, the agency signals that statutory protections override vendor conditions. Neither outcome is certain yet.
For safety-net hospitals already operating at thin margins, loss of 340B pricing on a major drug class can compress uncompensated care capacity. Eli Lilly's move affects not just procurement cost but clinical budgets downstream.
Hospitals need immediate compliance clarity
Hospital compliance officers should request Eli Lilly's formal requirements in writing and cross-reference them against 340B statute and HRSA guidance. Document any requests that appear to exceed statutory obligation; these will matter if HRSA investigation follows.
In parallel, escalate to your government relations team. HRSA has not yet responded publicly; early engagement with the agency and your state hospital association may influence the agency's posture if formal complaint arrives.
Do not assume the discount suspension is temporary or negotiable at the local level. Treat it as a hard stop until either Eli Lilly formally rescinds the requirement or HRSA issues guidance that overrides it.